Human Insulin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025

Human Insulin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025

  • April 2020 •
  • 108 pages •
  • Report ID: 5889842 •
  • Format: PDF
The global human insulin market reached a value of US$ 34.8 Billion in 2019. Human insulin (HI) is a form of synthetic insulin that is synthesized in laboratories for pharmaceutical use. It is bio-engineered by growing insulin proteins within E-coli bacteria (Escherichia coli) cells to mimic the properties of insulin naturally present in humans. The HI drugs are available in three kinds, namely rapid-acting, long-acting and premixed. They are used as a solution or suspension and are usually injected subcutaneously and aid in promoting the uptake of glucose from the blood into internal organs, such as fat cells, skeletal muscles and liver. They also inhibit hepatic glucose production, lipolysis and proteolysis and enhance protein synthesis in the body.

The increasing prevalence of obesity and diabetes across the globe is one of the key factors driving the growth of the market. Owing to sedentary lifestyles, growing geriatric population and unhealthy dietary habits, a greater number of individuals are suffering from chronic lifestyle diseases, thereby increasing the demand for insulin therapeutics. Furthermore, the growing requirement for biosimilar drugs, owing to their high efficiency and cost-effectiveness, is providing a boost to the market growth. Various technological advancements, such as the development of pen devices and safety pen needles, to administer HI in the body, are also creating a positive impact on the market growth. In comparison to standard needles, these safety pens ensure minimal injuries, discomfort and infections through bloodborne pathogen transmission. Other factors, including the increasing health consciousness among the masses and extensive research and development (R&D) in the field of biotechnology, are projected to drive the market further. Looking forward, the analyst expects the market to reach a value of US$ 58.3 Billion by 2025, exhibiting a CAGR of around 9% during 2020-2025.

Breakup by Product:
Drugs
Human Insulin Analogs and Biosimilars
Rapid Acting
Long Acting
Premixed
Human Insulin Biologics
Short Acting
Intermediate Acting
Premixed
Delivery Devices
Pens
Reusable Pens
Disposable Pens
Pen Needles
Standard Pen Needles
Safety Pen Needles
Syringes
Others

Breakup by Distribution Channel:
Retail Pharmacies
Hospital Pharmacies
Online Retail Stores
Others

Breakup by Disease Type:
Type I Diabetes
Type II Diabetes

Breakup by Region:
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined with some of the key players being B. Braun Melsungen AG, Becton Dickinson & Company, Biocon, Eli Lilly and Company, Julphar, Novo Nordisk, Pfizer, Sanofi, Sedico, Wockhardt, Ypsomed Holding, etc.

Key Questions Answered in This Report:
How has the global human insulin market performed so far and how will it perform in the coming years?
What are the key regional markets?
What is the breakup of the market based on the product type?
What is the breakup of the market based on the drug type?
What is the breakup of the market based on the delivery devices?
What is the breakup of the market based on the distribution channel?
What is the breakup of the market based on the disease type?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global human insulin market and who are the key players?
What is the degree of competition in the industry?